Table II. Summary of expression in transgenic founder lines.
| No. of founders (Fo) | No. of GFP+ Fo in Sp or PB | Myeloid cells | B cells | T cells | |
|---|---|---|---|---|---|
| A-GFP-B | 4 | 0 | ND | ND | ND |
| A-B-GFP | 3 | 0 | ND | ND | ND |
| 400 (p)-GFP | 7 | 1 | +/– | +/– | +/– |
| 600-GFP | 12 | 0 | ND | ND | ND |
| A-p-GFP | 8 | 4a | + | – | – |
| B-p-GFP | 27 | 4b | + | + | +/– |
| B-p-GFP-C | 10 | 8c | + | + | + |
The number of founders obtained and the number of GFP-positive founders in either peripheral blood (PB) or spleen (Sp) are shown. The expression patterns in different cell types are indicated as + or –.
aExpression in granulocytes in different founder lines ranged from 2.9 to 31% (GFP+).
bExpression in B cells ranged from 1.4 to 94% and in granulocytes from 0.2 to 49%.
cExpression in B cells ranged from 1.5 to 94%, in granulocytes from 0.4 to 99%, and in T cells from 1.7 to 99%.